X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bayer-issues-voluntary-recall-nationwide-vitrakvir-larotrectinib-oral-solution-20-mgml-due-presence
https://endpts.com/tissue-agnostic-drug-development-fda-oncology-center-offers-draft-guidance/
https://www.biospace.com/article/follow-up-data-on-bayer-s-larotrectinib-hints-at-potentially-curative-impact/
https://media.bayer.com/baynews/baynews.nsf/id/20E13B140081FE60C12586DC003CE87C?open&ref=irrefndcd
https://www.fiercebiotech.com/medtech/fda-approves-foundation-medicine-s-diagnostic-for-bayer-s-tumor-agnostic-med-vitrakvi
https://www.onclive.com/view/fda-approves-companion-diagnostic-for-larotrectinib-for-ntrk-tumors
http://www.pharmatimes.com/news/bayers_vitrakvi_shows_long-term_efficacy_in_trk_fusion-positive_cancers_1350760
https://www.onclive.com/web-exclusives/larotrectinib-data-further-demonstrate-strong-efficacy-in-trk-tumors#:~:text=Larotrectinib%2C%20which%20has%20been%20FDA,published%20in%20The%20Lancet%20Oncology.
http://www.pharmatimes.com/news/nice_issues_final_guidance_on_nhs_use_of_bayers_vitrakvi_1340956
https://en.prnasia.com/releases/global/bayer-and-origimed-reached-a-partnership-to-develop-a-next-generation-sequencing-ngs-based-companion-diagnostic-in-vitro-diagnostic-cdx-ivd-product-in-china-for-larotrectinib-for-ntrk-gene-fusion-detection-278942.shtml
http://www.pharmafile.com/news/546911/bayers-vitrakvi-becomes-first-tumour-agnostic-therapy-approved-nice-nhs-patients-ntrk-fu
https://www.reuters.com/article/us-bayer-vitrakvi-germany/german-drug-assessment-body-not-convinced-by-bayers-cancer-drug-vitrakvi-idUSKBN1ZF211
https://www.prnewswire.com/news-releases/bayer-announces-updated-analysis-for-vitrakvi-larotrectinib-demonstrating-high-response-rate-and-duration-of-response-of-nearly-three-years-in-adults-and-children-with-trk-fusion-cancer-300927157.html
http://www.pmlive.com/pharma_news/bayers_vitrakvi_scores_first_tumour-agnostic_drug_approval_in_eu_1302438
https://in.reuters.com/article/us-bayer-cancer-insight/inside-drugmakers-strategy-to-boost-cancer-medicines-with-lazarus-effect-idINKCN1VR0EA
https://www.in-pharmatechnologist.com/Article/2019/08/19/FDA-approves-Roche-s-tumour-agnostic-drug
https://www.biopharmadive.com/news/roche-rozlytrek-cancer-drug-approval-tumor-agnostic/561027/
https://www.biospectrumasia.com/news/90/14142/bayer-gets-eu-chmp-nod-for-precision-oncology-treatment-larotrectinib-.html
https://in.reuters.com/article/us-bayer-vitrakvi-ema/ema-panel-recommends-approving-bayers-cancer-drug-vitrakvi-idINKCN1UL1H0
http://www.pmlive.com/pharma_news/england_to_fast-track_tumour_agnostic_drugs_like_viktravi_if_the_price_is_right_1292151
https://endpts.com/roche-fields-first-approval-for-rozlytrek-in-the-run-up-to-a-showdown-with-eli-lilly-pfizer/
https://www.fiercepharma.com/pharma/pfizer-never-say-never-m-a-buys-oncology-innovator-array-for-11-4b
https://www.reuters.com/article/us-roche-cancer/roche-wins-japan-approval-for-personalized-cancer-drug-rozlytrek-idUSKCN1TJ0H4
https://www.prnewswire.com/news-releases/new-data-on-vitrakvi-larotrectinib-in-trk-fusion-cancer-patients-with-brain-metastases-or-primary-central-nervous-system-cns-tumors-300860988.html
https://www.fiercepharma.com/pharma/drugmakers-brought-15-new-oncology-meds-to-market-last-year-as-spending-continued-to-climb
https://www.biocentury.com/bc-extra/company-news/2019-05-29/bayer-taps-second-partner-develop-vitrakvis-companion-diagnostic
https://www.prnewswire.com/news-releases/bayer-announces-results-of-sub-group-analysis-for-vitrakvi-larotrectinib-in-patients-with-ntrk-gene-fusion-positive-metastatic-non-small-cell-lung-cancer-nsclc-300830799.html
https://www.fiercebiotech.com/biotech/bayer-posts-early-clinical-data-follow-up-to-loxo-s-vitrakvi
https://www.in-pharmatechnologist.com/Article/2019/02/21/Bayer-obtains-licensing-rights-to-TRK-inhibitor-from-Loxo
https://www.fiercepharma.com/pharma/pipeline-hungry-bayer-takes-full-vitrakvi-rights-from-lilly-as-roche-s-rival-gets-faster-fda
https://www.biopharmadive.com/news/as-lilly-deal-closes-bayer-secures-full-rights-to-loxos-vitrakvi/548584/
https://www.prnewswire.com/news-releases/bayer-to-obtain-full-rights-to-global-development-and-commercialization-of-oncology-compounds-vitrakvi-larotrectinib-and-bay-2731954-loxo-195-300796567.html
https://blogs.sciencemag.org/pipeline/archives/2019/02/04/2018-drug-approvals-a-closer-look?r3f_986=https://www.google.com/
https://www.fiercepharma.com/marketing/bayer-gets-program-for-super-bowl-liii-print-ad-kicks-off-cancer-testing-awareness-effort
https://www.fiercepharma.com/pharma/jpm-wrapup-must-reads-from-a-week-biopharma-news-chosen-by-you
http://www.evaluate.com/vantage/articles/news/deals/jp-morgan-2019-lilly-fans-ma-flames-loxo-oncology-deal
https://endpts.com/jpm19-starts-with-eli-lillys-8b-buyout-of-loxo-oncology/
https://www.statnews.com/2019/01/07/fda-plans-to-create-a-new-office-to-leverage-cutting-edge-science/
https://www.biospace.com/article/top-9-really-cool-life-science-discoveries-of-the-year/
Market Place
Share 
